Novel targets and technologies for CAR-T cells in multiple myeloma and acute myeloid leukemia

Curr Res Transl Med. 2018 May;66(2):37-38. doi: 10.1016/j.retram.2018.03.006. Epub 2018 Apr 11.

Authors

Sabrina Prommersberger¹, Hardikkumar Jetani², Sophia Danhof², Razieh Monjezi², Thomas Nerreter², Julia Beckmann², Herrmann Einsele², Michael Hudecek²

Affiliations

¹ Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany. Electronic address: prommersbe_s@ukw.de.
² Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.

PMID: 29655962
DOI: 10.1016/j.retram.2018.03.006

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Gene Transfer Techniques
Humans
Immunotherapy, Adoptive / methods*
Leukemia, Myeloid, Acute / immunology
Leukemia, Myeloid, Acute / therapy*
Molecular Targeted Therapy / methods
Molecular Targeted Therapy / trends
Multiple Myeloma / immunology
Multiple Myeloma / therapy*
Oncolytic Virotherapy / adverse effects
Oncolytic Viruses / physiology
Receptors, Antigen, T-Cell / physiology
Receptors, Antigen, T-Cell / therapeutic use
Receptors, Chimeric Antigen / metabolism
Receptors, Chimeric Antigen / therapeutic use*
Signaling Lymphocytic Activation Molecule Family / antagonists & inhibitors
Signaling Lymphocytic Activation Molecule Family / immunology
T-Lymphocytes / physiology*
fms-Like Tyrosine Kinase 3 / antagonists & inhibitors
fms-Like Tyrosine Kinase 3 / immunology

Substances

Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen
SLAMF7 protein, human
Signaling Lymphocytic Activation Molecule Family
FLT3 protein, human
fms-Like Tyrosine Kinase 3